Garabadu Debapriya, Krishnamurthy Sairam
a Pharmacology Laboratory, Department of Pharmaceutics , Indian Institute of Technology (Banaras Hindu University) , Varanasi , UP , India.
Pharm Biol. 2017 Dec;55(1):722-728. doi: 10.1080/13880209.2016.1268635.
Metformin attenuates type-2 diabetes mellitus (T2DM)-induced hepatic dysfunction and altered PI3K/Akt/GLUT-4 signalling in experimental studies. However, its effect on bicuculline-sensitive gamma amino butyric acid (GABA)-A receptor (GABAR)-mediated calcium-dependent PI3K/Akt/GLUT-4 signalling in liver challenged to T2DM has not been established.
The effectiveness of metformin on bicuculline-sensitive GABAR-mediated hepatic insulin signalling was carried out in presence or absence of bicuculline (2.0 mg/kg, i.p.) in experimental T2DM rats.
The whole experimental design was divided into three independent sets of experiments. Each set comprised seven groups of six male rats each. T2DM was induced in the animals by administering streptozotocin (45 mg/kg, i.p.) and nicotinamide (110 mg/kg, i.p.) at a time lag of 15 min except control group rats in three experiments. Metformin and/or bicuculline or wortmannin were administered once daily for one week from seventh day of streptozotocin injection in all the experimental sets.
Metformin attenuated T2DM-induced hyperglycaemia in glucose (40%) and insulin (50%) tolerance tests in rats. Metformin also attenuated T2DM-induced hyperglycaemia (40%), hyperinsulinaemia (30%), insulin resistance (50%) and β-cell dysfunction (300%) in the animals. Metformin did not attenuate T2DM-induced decrease in rat hepatic intracellular calcium. Further, metformin mitigated T2DM-induced decrease in hepatic phosphorylated Akt and GLUT-4 translocation in the animals. The anti-diabetic activity of metformin was abolished by wortmannin but not with bicuculline co-administration in T2DM animals.
These results suggest that metformin ameliorated T2DM-induced hepatic insulin resistance through bicuculline-sensitive GABA receptor-independent PI3K/Akt/GLUT-4 signalling pathway in animals.
在实验研究中,二甲双胍可减轻2型糖尿病(T2DM)诱导的肝功能障碍,并改变PI3K/Akt/GLUT-4信号通路。然而,其对T2DM攻击的肝脏中荷包牡丹碱敏感的γ-氨基丁酸(GABA)-A受体(GABAR)介导的钙依赖性PI3K/Akt/GLUT-4信号通路的影响尚未明确。
在实验性T2DM大鼠中,研究二甲双胍在存在或不存在荷包牡丹碱(2.0mg/kg,腹腔注射)的情况下,对荷包牡丹碱敏感的GABAR介导的肝脏胰岛素信号传导的有效性。
整个实验设计分为三组独立实验。每组包括七组,每组六只雄性大鼠。除三个实验中的对照组大鼠外,通过在15分钟的时间间隔内腹腔注射链脲佐菌素(45mg/kg)和烟酰胺(110mg/kg)诱导动物发生T2DM。在所有实验组中,从链脲佐菌素注射的第七天开始,每天一次给予二甲双胍和/或荷包牡丹碱或渥曼青霉素,持续一周。
在大鼠的葡萄糖(40%)和胰岛素(50%)耐量试验中,二甲双胍减轻了T2DM诱导的高血糖症。二甲双胍还减轻了动物中T2DM诱导的高血糖症(40%)、高胰岛素血症(30%)、胰岛素抵抗(50%)和β细胞功能障碍(300%)。二甲双胍并未减轻T2DM诱导的大鼠肝脏细胞内钙的减少。此外,二甲双胍减轻了T2DM诱导的动物肝脏磷酸化Akt和GLUT-4易位的减少。渥曼青霉素消除了二甲双胍在T2DM动物中的抗糖尿病活性,但与荷包牡丹碱共同给药则没有。
这些结果表明,二甲双胍通过动物中荷包牡丹碱敏感的GABA受体非依赖性PI3K/Akt/GLUT-4信号通路改善了T2DM诱导的肝脏胰岛素抵抗。